6CM
TRDA icon

683 Capital Management’s Entrada Therapeutics TRDA Stock Holding History

683 Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,355
Closed -$150K – 247
2023
Q1 		$150K Hold
10,355
– – 0.01% 203
2022
Q4 		$140K Buy
+10,355
New +$182K 0.01% 224

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

683 Capital Management's TRDA Position: Q2 2023 in Review

683 Capital Management sold out of Entrada Therapeutics (TRDA) in Q2 2023, closing a stake of 10,355 shares — an estimated $150K sold.

683 Capital Management first reported a position in TRDA in Q4 2022 and held it in 2 quarters. The position peaked at $150K in Q1 2023. 56 funds tracked by Wall St. Rank hold TRDA as of Q2 2023.

  • 683 Capital Management reported no remaining Entrada Therapeutics position as of Q2 2023 after selling out during the quarter.
  • 683 Capital Management sold 10,355 Entrada Therapeutics shares in Q2 2023, an estimated $150K.
  • 683 Capital Management first reported a position in Entrada Therapeutics in Q4 2022 and held it in 2 quarters.
  • 683 Capital Management's Entrada Therapeutics position peaked at $150K in Q1 2023.
  • 56 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.